Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Protocol increases trade and international cooperation

BIO 22 (Biotechnology Innovation Organization, BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and in 30+ countries, “The Biosafety Protocol-An Overview”, https://archive.bio.org/articles/biosafety-protocol-overview, Accessed June 19, 2022)//AS

“THE PROPOSED BIOSAFETY PROTOCOL: KEY ISSUES The Parties to the Convention on Biological Diversity intended for the Biosafety Protocol to govern the transboundary movement of Living Modified Organisms (LMOs) that may have an adverse effect on the conservation and sustainable use of biological diversity. Jakarta Decision II/5, which established the negotiating parameters, provides that the Protocol: Not exceed the scope of the Convention; Not override or duplicate any other international legal instrument; Not unduly hinder access to and transfer of technology, and Be efficient, effective and minimize unnecessary negative impacts on biotechnology research and development. To serve the goals of the Convention and meet the conditions specified by Decision II/5, the Protocol must provide for the conservation and sustainable use of biological diversity, while at the same time allowing for the development and use of valuable new products. It must also be consistent with other international agreements and not cause unwarranted disruptions in the transboundary movement and trade of essential materials. To meet these objectives we recommend that the Biosafety Protocol be built on the following key positions: The scope of the Protocol must govern only those LMOs and intended uses that may have a significant adverse effect on biodiversity. Extending the scope of the Protocol cover LMOs and intended uses that, based on scientific principles, will not have significant adverse effects on biodiversity would impede access to agricultural, medical and other beneficial products without a compensatory increase in biodiversity protection. LMOs and intended uses that realistically will not have adverse effects on biodiversity should not be included in the scope of the Protocol. This will allow resources to be focused more effectively. Appropriate exclusions include, at a minimum, LMOs that have been reviewed and accepted for commercial or research use by the importing country; LMOs destined for contained use or transport; commodities approved for commercialization, and pharmaceuticals. The Advanced Informed Agreement (AIA) procedures should be applied only to those LMOs and intended uses that may realistically have a significant adverse effect on biodiversity. A "Notice of First Shipment" should be the primary mechanism to inform countries of the proposed shipment of an LMO. An AIA provision that requires written notification and consent for all LMOs will be extremely costly, demanding and burdensome for governments to administer, especially as the number of shipments covered by the Protocol increases. Moreover, if an intricate, lengthy and repetitive AIA process is applied to all LMOs, access to food, fiber and health care products will be impeded as will the development of new products. The Protocol must be consistent with international trade rules. If the scope of the Protocol is unnecessarily broad and the AIA procedure is excessively burdensome, the Protocol could have serious negative impacts on the trade. As such, the Protocol's scope and AIA provisions must be limited to those LMOs and intended uses that may realistically have a significant adverse effect on biodiversity. The decision to approve or deny shipment of an LMO covered by the Protocol must be based on sound science regarding real or reasonably anticipated effects on biodiversity. Speculative, non-significant adverse effects on biodiversity must not be used to reject products. Discrimination of products based on their production techniques must also be avoided. The Protocol must provide for the protection of confidential business information and other intellectual property. The Protocol must contain clear and appropriate procedures for designating and protecting confidential information and intellectual property shared in conjunction with the notification provisions of the Protocol. Procedures for resolving disputes over confidentiality claims regarding protected and privileged information must also be defined in the Protocol. In the absence of protection afforded by such procedures, companies and institutions will be reluctant to engage in commercial trade, international product development or exchange of research materials involving LMOs covered by the Protocol. The Protocol should not create an international system of liability. Existing national and regional legal systems should be relied upon to determine what triggers legal liability for harm to biodiversity, the nature and extent of harm that can be compensated, and the procedural system to obtain relief from liable parties.”

Sign in to recut, update, or save this card.